BR9408506A - Compostos neuroprotetores - Google Patents

Compostos neuroprotetores

Info

Publication number: BR9408506A
Authority: BR; Brazil
Prior art keywords: pct; sec; date; neuroprotective compounds; pub
Prior art date: 1994-01-31

Application number

BR9408506A

Other languages

English (en)

Inventor

Todd W Butler

Bertrand L Chenard

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-31

Filing date

1994-11-21

Publication date

1997-08-05

1994-11-21 Application filed by Pfizer filed Critical Pfizer

1997-08-05 Publication of BR9408506A publication Critical patent/BR9408506A/pt

Links

150000001875 compounds Chemical class 0.000 title 1
230000000324 neuroprotective effect Effects 0.000 title 1
JQQWDYJWDCIVKQ-QUCCMNQESA-N (3r,4s)-3-(4-benzyl-4-hydroxypiperidin-1-yl)-3,4-dihydro-2h-chromene-4,7-diol Chemical compound C1CN([C@H]2[C@H](C3=CC=C(O)C=C3OC2)O)CCC1(O)CC1=CC=CC=C1 JQQWDYJWDCIVKQ-QUCCMNQESA-N 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BR9408506A 1994-01-31 1994-11-21 Compostos neuroprotetores BR9408506A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18947994A	1994-01-31	1994-01-31
PCT/IB1994/000365 WO1995020587A1 (en)	1994-01-31	1994-11-21	Neuroprotective chroman compounds

Publications (1)

Publication Number	Publication Date
BR9408506A true BR9408506A (pt)	1997-08-05

Family

ID=22697514

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR9408506A BR9408506A (pt)	1994-01-31	1994-11-21	Compostos neuroprotetores
BR9500380A BR9500380A (pt)	1994-01-31	1995-01-30	Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR9500380A BR9500380A (pt)	1994-01-31	1995-01-30	Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero

Country Status (27)

Country	Link
US (1)	US5744483A (pt)
EP (1)	EP0741724B1 (pt)
JP (1)	JP2866743B2 (pt)
CN (1)	CN1048247C (pt)
AT (1)	ATE183184T1 (pt)
AU (1)	AU684568B2 (pt)
BR (2)	BR9408506A (pt)
CA (1)	CA2182101C (pt)
CO (1)	CO4230161A1 (pt)
CZ (1)	CZ286757B6 (pt)
DE (1)	DE69420053T2 (pt)
DK (1)	DK0741724T3 (pt)
EG (1)	EG20672A (pt)
ES (1)	ES2134361T3 (pt)
FI (1)	FI113769B (pt)
GR (1)	GR3031356T3 (pt)
HU (1)	HU221633B1 (pt)
IL (1)	IL112415A (pt)
MY (1)	MY111623A (pt)
NO (1)	NO309190B1 (pt)
NZ (1)	NZ275151A (pt)
PE (1)	PE43795A1 (pt)
PL (1)	PL179448B1 (pt)
RU (1)	RU2126404C1 (pt)
TW (1)	TW449591B (pt)
WO (1)	WO1995020587A1 (pt)
ZA (1)	ZA95692B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997010240A1 (en) *	1995-09-15	1997-03-20	Pfizer Inc.	Phenol derivatives with pharmaceutical activity
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
UA73981C2 (en) *	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
PA8525601A1 (es) *	2000-08-21	2002-04-25	Hoffmann La Roche	Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
EP1674087A1 (en)	2000-10-02	2006-06-28	Pfizer Products Inc.	Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
ZA200108038B (en) *	2000-10-02	2003-04-01	Pfizer Prod Inc	Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
ATE352302T1 (de) *	2001-07-26	2007-02-15	Merck Patent Gmbh	Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
RU2240113C1 (ru) *	2003-01-23	2004-11-20	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова	Способ экстренной медикаментозной помощи при острой травме спинного мозга
CA2547283C (en) *	2003-11-26	2010-11-09	Pfizer Products Inc.	Aminopyrazole derivatives as gsk-3 inhibitors
CN101300246A (zh)	2005-11-03	2008-11-05	弗·哈夫曼-拉罗切有限公司	作为5－ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物
AR059075A1 (es) *	2006-01-20	2008-03-12	Schering Corp	Bencesulfonil - cromano , tiocromano tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
RU2418578C1 (ru) *	2009-12-08	2011-05-20	Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА
EP2522647B1 (en) *	2011-05-10	2014-04-30	DSM IP Assets B.V.	Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3294804A (en) *	1961-01-27	1966-12-27	Sterling Drug Inc	1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (pt) *	1966-09-27	1968-01-22
GB1495526A (en) *	1974-05-31	1977-12-21	Beecham Group Ltd	Chroman derivatives
US4016281A (en) *	1975-02-22	1977-04-05	Merck Patent Gesellschaft Mit Beschrankter Haftung	Tetralone and indanone compounds
US4082755A (en) *	1977-02-14	1978-04-04	Janssen Pharmaceutica N.V.	1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (fr) *	1978-07-03	1980-02-07	Sandoz Ag	Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4358456A (en) *	1980-05-03	1982-11-09	John Wyeth & Brother Limited	Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) *	1980-12-04	1982-07-08	C.H. Boehringer Sohn, 6507 Ingelheim	Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE23718T1 (de) *	1981-09-25	1986-12-15	Beecham Group Plc	Benzopyran-verbindungen mit pharmazeutischer wirkung.
EP0093534A1 (en) *	1982-04-28	1983-11-09	Beecham Group Plc	Novel chromanols
ES523609A0 (es) *	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
GB8308064D0 (en) *	1983-03-24	1983-05-05	Beecham Group Plc	Active compounds
FR2546166B1 (fr) *	1983-05-19	1985-10-25	Synthelabo	Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
FR2581993B1 (fr) *	1985-05-14	1988-03-18	Synthelabo	Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) *	1986-06-26	1990-09-18	Ciba-Geigy Corporation	Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) *	1988-02-19	1990-11-06	Eli Lilly And Company	Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) *	1988-07-12	1992-07-10	Synthelabo	Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) *	1989-02-07	1990-11-06	Transitions Research Corporation	Dual bumper-light curtain obstacle detection sensor
US4902695A (en) *	1989-02-13	1990-02-20	Eli Lilly And Company	Excitatory amino acid receptor antagonists
WO1990014087A1 (en) *	1989-05-17	1990-11-29	Pfizer Inc.	2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) *	1990-02-06	2003-09-29	Pfizer, Inc.,	Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/en not_active Ceased
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 EP EP94931668A patent/EP0741724B1/en not_active Expired - Lifetime
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 CA CA002182101A patent/CA2182101C/en not_active Expired - Fee Related
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown

Also Published As

Publication number	Publication date
ZA95692B (en)	1996-07-30
CN1048247C (zh)	2000-01-12
RU2126404C1 (ru)	1999-02-20
PL179448B1 (pl)	2000-09-29
MY111623A (en)	2000-09-27
GR3031356T3 (en)	2000-01-31
CA2182101C (en)	1999-08-03
NO309190B1 (no)	2000-12-27
DK0741724T3 (da)	1999-12-20
NZ275151A (en)	1998-02-26
BR9500380A (pt)	1995-10-17
US5744483A (en)	1998-04-28
IL112415A (en)	1999-07-14
AU684568B2 (en)	1997-12-18
DE69420053T2 (de)	1999-11-25
NO963186D0 (no)	1996-07-30
WO1995020587A1 (en)	1995-08-03
HUT75942A (en)	1997-05-28
JPH09501698A (ja)	1997-02-18
JP2866743B2 (ja)	1999-03-08
CN1142825A (zh)	1997-02-12
NO963186L (no)	1996-07-30
CO4230161A1 (es)	1995-10-19
PE43795A1 (es)	1995-12-09
HU221633B1 (hu)	2002-12-28
FI113769B (fi)	2004-06-15
EP0741724B1 (en)	1999-08-11
CA2182101A1 (en)	1995-08-03
CZ286757B6 (en)	2000-06-14
FI950403A0 (fi)	1995-01-30
CZ225696A3 (en)	1997-01-15
IL112415A0 (en)	1995-03-30
PL315681A1 (en)	1996-11-25
ATE183184T1 (de)	1999-08-15
HU9602100D0 (en)	1996-09-30
FI950403L (fi)	1995-08-01
TW449591B (en)	2001-08-11
ES2134361T3 (es)	1999-10-01
EG20672A (en)	1999-11-30
EP0741724A1 (en)	1996-11-13
AU8066394A (en)	1995-08-15
DE69420053D1 (de)	1999-09-16

Legal Events

Date	Code	Title
1999-06-15	EG	Technical examination (opinion): publication of technical examination (opinion)
1999-11-16	FC	Decision: refusal
2000-04-04	FC	Decision: refusal
2000-04-04	HIFC	Refusal cancelled
2000-08-01	CKFC	Appeal: appeal against refusal

Publication	Publication Date	Title
ATE206611T1 (de)	2001-10-15	Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
EG20672A (en)	1999-11-30	Neuroprotective compounds
DE59508891D1 (de)	2001-01-11	Hautpflegemittel
DE69529670D1 (de)	2003-03-27	Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DK0946162T3 (da)	2004-03-01	Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
ES2147616T3 (es)	2000-09-16	Derivados de piperidina con actividad antagonista del paf.
RU94044356A (ru)	1996-10-10	Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
NO20012310D0 (no)	2001-05-10	Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
ATE191342T1 (de)	2000-04-15	Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
EP0653936A1 (en)	1995-05-24	USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL] -3-HYDROXY-1,4-NAPHTOQUINONE IN THE TREATMENT OF CANCER.
RU94044487A (ru)	1996-10-20	Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
NZ268914A (en)	1999-06-29	Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
EE04951B1 (et)	2008-02-15	R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks
ATE168697T1 (de)	1998-08-15	Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
FR2718965B1 (fr)	1996-05-24	Nouvelle application thérapeutique de la spiramycine.